SEC Form 4 · accession 0001873394-26-000005
Entrada Therapeutics, Inc. · TRDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natarajan Sethuraman
Officer — President, Research & Develop.
Period of report
Sep 2, 2026
Accepted (ET)
Sep 3, 2026 · 5:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001689375
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 2, 2026 | F | 2,079 | $7.1439 | D | 214,238 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.